Première réunion annuelle du projet SOLVE !
Première réunion annuelle du projet SOLVE !
L’équipe EUCLID-MART était présente à la réunion annuelle du projet SOLVE – Sustainable Covid-19 Vaccination for Long-term Vaccine Immunity and Effectiveness, qui s’est déroulée les 6 et 7 mai 2025 à Madrid et animée par Mariano Esteban (CSIC). Ce projet vise à décoder les mécanismes à l’origine de l’immunité à long terme en comparant directement les plateformes vaccinales et en explorant de nouveaux concepts de vaccins contre le Covid-19. EUCLID-MART s’engage à soutenir une recherche clinique collaborative solide qui génère des résultats significatifs en matière de santé publique ! En tant que responsable du Work Package « Clinical Trial », Linda Wittkop pour EUCLID-MART, participe activement à la réalisation d’un essai clinique à promotion ANRS MIE, sur de petites cohortes de volontaires. Nous sommes fiers de contribuer à cet effort de collaboration qui façonne l’avenir de la vaccination contre la COVID-19 !
Project summary
Despite the rapid development of various SARS-CoV-2 vaccines, the control of the pandemic is hampered by the constant emergence of SARS-CoV-2 variants escaping vaccine-induced immunity and the waning of immunity. SOLVE will tackle these challenges by deciphering the mechanisms of induction of long-lasting immunity and evaluating new vaccine platforms. To achieve this goal, an integrated plan has been developed including six pillars: 1) Vaccine discovery and design; 2) Head-to-head evaluation of the immune response and long-lasting immunity induced by four vaccine platforms in the preclinical setting; 3) Validation of the pre-clinical results in an experimental medicine trial (EMT); 4) Immune mechanisms of long-lasting immunity; 5) Data Science; 6) Determinants of population adherence to vaccination. New immunogens including key mutations from most recent variants in RBD and Nucleocapsid sequences highly conserved across Sarbecoviruses, will be delivered through: antigen-targeting to dendritic cells (DC), i.e. CD40 DC-targeting, nanoparticles, a MVA vector and 2nd generations of mRNAs. SOLVE will evaluate in depth the immunogenicity of these vaccines in the preclinical setting, and in an EMT testing two vaccines, i.e. CD40 DC-targeting and MVA with available GMP clinical lots. SOLVE will benefit from the most advanced technologies to identify the mechanisms of long-lasting immunity. Integrative analyses of high throughput data, including from large cohorts, will provide insights for identification of factors (demographics, vaccines, immunity) which impact quality and longevity of immunity. SOLVE will investigate stakeholders’s perspective on the acceptability of large vaccination campaigns to improve implementation of next generation of vaccines in a preparedness track. The consortium gathers 8 renowned public/private institutions supported by a governance facilitating fast sharing of information to keep up with a tight schedule imposed by the pandemic.
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Executive Agency (REA). Neither the European Union nor the granting authority can be held responsible for them. Grant Agreement: 101137185
Lancement de deux nouvelles plateformes
Lancement de deux nouvelles plateformes !
- OPEN-ReMIE : un « plan blanc » de la recherche clinique pour faire face aux futures épidémies.
- I-REIVAC-Émergence : un pas décisif pour la recherche clinique française en vaccinologie contre les maladies infectieuses émergentes.
La réunion de lancement s’est tenue le 31 mars dernier !
